home / stock / syrs / syrs quote
Last: | $5.13 |
---|---|
Change Percent: | 0.96% |
Open: | $5.15 |
Close: | $5.13 |
High: | $5.34 |
Low: | $5.05 |
Volume: | 95,319 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.13 | $5.15 | $5.13 | $5.34 | $5.05 | 95,319 | 05-03-2024 |
$5.2 | $5.53 | $5.2 | $5.64 | $5.185 | 301,219 | 05-02-2024 |
$5.44 | $5.29 | $5.44 | $5.6499 | $5.28 | 199,558 | 05-01-2024 |
$5.4 | $5.29 | $5.4 | $5.4265 | $5.227 | 94,794 | 04-30-2024 |
$5.38 | $5.08 | $5.38 | $5.47 | $5.045 | 113,794 | 04-29-2024 |
$5.04 | $5.03 | $5.04 | $5.1203 | $4.99 | 44,534 | 04-26-2024 |
$5.1 | $4.94 | $5.1 | $5.15 | $4.92 | 128,577 | 04-25-2024 |
$5.07 | $5.2 | $5.07 | $5.2 | $5 | 89,634 | 04-24-2024 |
$5.14 | $4.98 | $5.14 | $5.32 | $4.98 | 172,646 | 04-23-2024 |
$4.99 | $4.57 | $4.99 | $5.03 | $4.57 | 151,987 | 04-22-2024 |
$4.54 | $4.67 | $4.54 | $4.72 | $4.4 | 262,916 | 04-19-2024 |
$4.72 | $5.04 | $4.72 | $5.06 | $4.72 | 119,453 | 04-18-2024 |
$5.11 | $5.55 | $5.11 | $5.67 | $5.09 | 126,079 | 04-17-2024 |
$5.56 | $5.27 | $5.56 | $5.76 | $5.18 | 287,406 | 04-16-2024 |
$5.35 | $5.34 | $5.35 | $5.63 | $5.24 | 148,071 | 04-15-2024 |
$5.39 | $5.95 | $5.39 | $5.95 | $5.33 | 221,741 | 04-12-2024 |
$5.92 | $5.58 | $5.92 | $5.94 | $5.4758 | 258,228 | 04-11-2024 |
$5.53 | $5.44 | $5.53 | $5.63 | $5.2063 | 238,204 | 04-10-2024 |
$5.5 | $4.74 | $5.5 | $5.84 | $4.7 | 992,207 | 04-09-2024 |
$4.5 | $4.66 | $4.5 | $4.7 | $4.495 | 155,108 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 whi...
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in ...